The OPTIMIZE randomized trial to assess safety and efficacy of the Svelte IDS and RX Sirolimus-eluting coronary stent Systems for the Treatment of atherosclerotic lesions: Trial design and rationale - 07/11/19
Background |
Coronary stenting without angioplasty pretreatment (direct stenting) may simplify procedures in appropriate lesions. Direct stenting is facilitated by smaller profile coronary stent platforms. The present study was designed for regulatory approval of a novel drug-eluting coronary stent and incorporates both randomized comparison for non-inferiority to an approved predicate device as well as a nested evaluation of subjects eligible for direct stenting.
Study Design and Objectives |
Prospective, single-blind, randomized, active-control, multi-center study designed to assess the safety and efficacy of the novel Svelte sirolimus-eluting stent (SES) systems. A total of 1630 subjects with up to 3 target lesions will be randomized 1:1 to the Svelte SES versus either the Xience or Promus everolimus-eluting stents (control). Randomization will be stratified by whether or not a direct stenting strategy is planned by the investigator. The primary endpoint is target lesion failure (TLF) at 12 months post index procedure, defined as cardiac death, target vessel myocardial infarction, or clinically driven target lesion revascularization, and the primary analysis is a non-inferiority test with a non-inferiority margin of 3.58%. Secondary clinical endpoints include individual components of TLF, stent thrombosis and measures of procedural resource utilization including contrast administration, fluoroscopy exposure and procedural resource utilization as well as costs.
Conclusion |
The OPTMIZE Trial will evaluate the safety, efficacy and clinical value of the novel Svelte SES in subjects with up to 3 lesions, and will provide a comparison of direct stenting between randomized devices.
Le texte complet de cet article est disponible en PDF.Abbreviations : ARC, BMS, CEC, DAPT, DES, EES, IDS, IFU, IVUS, LLL, PCI, MACE, MI, MLD, RX, SES, STEMI, TIMI, TLF, TLR, TVF, TVR, US
Plan
| RCT# NCT03190473 |
|
| Sorin Jakob Brener, MD served as guest editor for this article. |
Vol 216
P. 82-90 - octobre 2019 Retour au numéro
Article précédent
- Expanding opportunities to understand quality and outcomes of peripheral vascular interventions: The ACC NCDR PVI Registry
- W. Schuyler Jones, Kevin F. Kennedy, Beau M. Hawkins, Robert R. Attaran, Eric A. Secemsky, Faisal Latif, Nicolas W. Shammas, Dmitriy N. Feldman, Herbert D. Aronow, Bruce Gray, Ehrin J. Armstrong, P. Michael Grossman, Kalon K.L. Ho, Anand Prasad, Michael R. Jaff, Kenneth Rosenfield, Thomas T. Tsai
- Rationale and design of a nurse-led intervention to extend the HIV treatment cascade for cardiovascular disease prevention trial (EXTRA-CVD)
- Nwora Lance Okeke, Allison R. Webel, Hayden B. Bosworth, Angela Aifah, Gerald S. Bloomfield, Emily W. Choi, Sarah Gonzales, Sarah Hale, Corrilynn O. Hileman, Virginie Lopez-Kidwell, Charles Muiruri, Megan Oakes, Julie Schexnayder, Valerie Smith, Rajesh Vedanthan, Chris T. Longenecker
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?